### Approval Package for:

**APPLICATION NUMBER:** 209379Orig1s000

<table>
<thead>
<tr>
<th>Trade Name:</th>
<th>Selenious Acid Injection, for intravenous use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Generic or Proper Name:</td>
<td>Selenious Acid Injection, USP, 60 mcg/mL</td>
</tr>
<tr>
<td>Sponsor:</td>
<td>American Regent, Inc.</td>
</tr>
<tr>
<td>Approval Date:</td>
<td>April 30, 2019</td>
</tr>
<tr>
<td>Indication:</td>
<td>Is a trace element indicated in adult and pediatric patients as a source of selenium for parental nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.</td>
</tr>
</tbody>
</table>
### CONTENTS

Reviews / Information Included in this NDA Review.

<table>
<thead>
<tr>
<th>Review Type</th>
<th>Included</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td>X</td>
</tr>
<tr>
<td>Other Action Letters</td>
<td>X</td>
</tr>
<tr>
<td>Labeling</td>
<td>X</td>
</tr>
<tr>
<td>REMS</td>
<td>X</td>
</tr>
<tr>
<td>Officer/Employee List</td>
<td>X</td>
</tr>
<tr>
<td>Multidiscipline Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>- Summary Review</td>
<td></td>
</tr>
<tr>
<td>- Office Director</td>
<td></td>
</tr>
<tr>
<td>- Cross Discipline Team Leader</td>
<td></td>
</tr>
<tr>
<td>- Clinical</td>
<td></td>
</tr>
<tr>
<td>- Non-Clinical</td>
<td></td>
</tr>
<tr>
<td>- Statistical</td>
<td></td>
</tr>
<tr>
<td>- Clinical Pharmacology</td>
<td></td>
</tr>
<tr>
<td>Product Quality Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Clinical Microbiology / Virology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Other Reviews</td>
<td>X</td>
</tr>
<tr>
<td>Risk Assessment and Risk Mitigation Review(s)</td>
<td></td>
</tr>
<tr>
<td>Proprietary Name Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
<td></td>
</tr>
</tbody>
</table>
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

209379Orig1s000

APPROVAL LETTER
NDA 209379

American Regent, Inc.
Attention: Marsha E. Simon
Director, Clinical Regulatory Affairs
800 Adams Avenue, Suite 100
Norristown, PA 19403

Dear Ms. Simon,

Please refer to your New Drug Application (NDA) dated and received on October 31, 2018, submitted under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Selenious Acid Injection, USP, 60 mcg/mL.

This new drug application provides for the use of Selenious Acid Injection in adult and pediatric patients as a source of selenium for parental nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.

APPROVAL & LABELING

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

We note that your April 30, 2019, submission includes final printed labeling (FPL) for your Prescribing Information. We have not reviewed this FPL. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As, available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf
The SPL will be accessible via publicly available labeling repositories.

**CARTON AND CONTAINER LABELING**

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling or carton and container labeling submitted on April 10, 2019, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (April 2018, Revision 5). For administrative purposes, designate this submission “Final Printed Carton and Container Labeling for approved NDA 209379.” Approval of this submission by FDA is not required before the labeling is used.

Please submit one market package of the drug product when it is available to the following address:

Thao M. Vu, R.Ph  
Food and Drug Administration  
Center for Drug Evaluation and Research  
White Oak Building 22, Room: 5232  
10903 New Hampshire Avenue  
Silver Spring, Maryland  
Use zip code 20903 if shipping via United States Postal Service (USPS).  
Use zip code 20993 if sending via any carrier other than USPS (e.g., UPS, DHL, FedEx).

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

This product is appropriately labeled for use in ages 0 to 17 years for this indication.

We are deferring the required pediatric assessment for patients weighing less than 7 kilograms for this application until an age-appropriate formulation is developed for this pediatric subpopulation.

Your deferred pediatric study required under section 505B(a) of the Federal Food, Drug, and Cosmetic Act is a required postmarketing study. The status of this postmarketing study must be reported annually according to 21 CFR 314.81 and section 505B(a)(4)(C) of the Federal Food, Drug, and Cosmetic Act. This required study is listed below.

3613-1 Develop an age-appropriate formulation to ensure accurate dosing by volume for pediatric patients weighing less than 7 kg
Final Report Submission: 08/2020

Reports of this required pediatric postmarketing study must be submitted as a new drug application (NDA) or as a supplement to your approved NDA with the proposed labeling changes you believe are warranted based on the data derived from these studies. When submitting the reports, please clearly mark your submission "SUBMISSION OF REQUIRED PEDIATRIC ASSESSMENTS" in large font, bolded type at the beginning of the cover letter of the submission.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the Prescribing Information, Medication Guide, and Patient Package Insert (as applicable) to:

OPDP Regulatory Project Manager
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705-1266

Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM443702.pdf).

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).
If you have any questions, call Thao Vu, Regulatory Project Manager, at (240) 402-2690.

Sincerely,

{See appended electronic signature page}

Bindi Nikhar, M.D.,
(Acting) Deputy Division Director,
Division of Gastroenterology and Inborn Errors Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling:
Prescribing Information
Carton and Container Labeling
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

BINDI M NIKHAR
04/30/2019 06:26:01 PM